Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of efficacy and safety of insulin detemir in combination with insulin aspart and biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in type 2 diabetes mellitus.

Trial Profile

Comparison of efficacy and safety of insulin detemir in combination with insulin aspart and biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in type 2 diabetes mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Insulin aspart; Insulin aspart/insulin protamine aspart; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PreFER
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Jul 2009 Actual end date (1 Mar 2005) added as reported by ClinicalTrials.gov.
    • 01 Jan 2009 Results have been published in Diabetes, Obesity and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top